Other equities analysts also recently issued research reports about the stock. Zacks Investment Research downgraded shares of OpGen from a “hold” rating to a “sell” rating in a research note on Tuesday, April 5th. Alliance Global Partners lowered their target price on shares of OpGen from $4.35 to $3.00 in a research note on Wednesday, January 12th.
NASDAQ:OPGN opened at $0.76 on Friday. The company has a fifty day simple moving average of $0.81 and a two-hundred day simple moving average of $1.26. The company has a market cap of $35.38 million, a price-to-earnings ratio of -0.63 and a beta of -0.74. The company has a quick ratio of 1.93, a current ratio of 2.00 and a debt-to-equity ratio of 0.17. OpGen has a 52 week low of $0.67 and a 52 week high of $3.72.
Several hedge funds have recently modified their holdings of OPGN. Millennium Management LLC acquired a new position in shares of OpGen during the second quarter worth $80,000. Geode Capital Management LLC lifted its position in OpGen by 10.3% in the third quarter. Geode Capital Management LLC now owns 353,208 shares of the medical research company’s stock valued at $1,017,000 after acquiring an additional 32,875 shares during the last quarter. Renaissance Technologies LLC lifted its position in OpGen by 74.6% in the third quarter. Renaissance Technologies LLC now owns 151,500 shares of the medical research company’s stock valued at $436,000 after acquiring an additional 64,747 shares during the last quarter. Dimensional Fund Advisors LP purchased a new stake in OpGen in the third quarter valued at $154,000. Finally, Marshall Wace LLP purchased a new stake in OpGen in the third quarter valued at $744,000. Hedge funds and other institutional investors own 7.74% of the company’s stock.
OpGen Company Profile (Get Rating)
OpGen, Inc is a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. It also engages in the development of molecular information products and services for global healthcare settings. It also offers guidance to clinicians about life threatening infections, improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms (MDROs).
- Get a free copy of the StockNews.com research report on OpGen (OPGN)
- Lululemon Rises On Wave Of Price Target Increases
- The Top Is In For Infosys
- Is Nvidia (NASDAQ: NVDA) About To Rip Higher?
- 3 Stellar Steel Stocks to Buy Now
- Bed Bath & Beyond Uncovers The Problem With Q1 Earnings Season
Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.